BiotechTube

patisiran (ALN-TTR02)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

TTR-mediated Amyloidosis

Conditions

TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related

Trial Timeline

— → —

NCT ID
NCT02939820

About patisiran (ALN-TTR02)

patisiran (ALN-TTR02) is a pre-clinical stage product being developed by Alnylam Pharmaceuticals for TTR-mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02939820. Target conditions include TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial.

What happened to similar drugs?

0 of 1 similar drugs in TTR-mediated Amyloidosis were approved

Approved (0) Terminated (0) Active (1)
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02939820Pre-clinicalCompleted

Competing Products

7 competing products in TTR-mediated Amyloidosis

See all competitors
ProductCompanyStageHype Score
ALN-TTR02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
ALN-TTRSC (revusiran) for subcutaneous administrationAlnylam PharmaceuticalsPhase 2
32
PatisiranAlnylam PharmaceuticalsPhase 2
32
ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
Revusiran (ALN-TTRSC)Alnylam PharmaceuticalsPhase 2
32
patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
37
ALN-TTR02 (patisiran) administered by intravenous (IV) infusionAlnylam PharmaceuticalsPhase 2
32